LSTA · Lisata Therapeutics, Inc. · Executive Compensation
$1.00
-0.01 (-0.91%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and existing capital resources, management has concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of twelve months from the date of issuance of the accompanying consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$8.97M
Shares
9.01M
Volume · Oct 23
45.56K
Avg daily vol (3M)
295.64K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| David J. Mazzo | Chief Executive Officer | $1,147,359 |
| Kristen K. Buck | M.D., Former Executive Vice President R&D and Chief Medical Officer | $736,418 |
| James Nisco | Senior Vice President, Finance and Treasury and Chief Accounting Officer | $433,464 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| David J. Mazzo | Chief Executive Officer | $1,691,174 |
| David Mazzo | President and Chief Executive Officer | $1,691,174 |
| Kristen K. Buck | M.D., Former Executive Vice President R&D and Chief Medical Officer | $1,065,061 |
| Kristen Buck | M.D, Executive Vice President of Research & Development and Chief Medical Officer | $1,065,061 |
| James Nisco | Senior Vice President, Finance and Treasury and Chief Accounting Officer | $516,166 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| David J. Mazzo | President and Chief Executive Officer | $1,408,382 |
| David Mazzo | President and Chief Executive Officer | $1,408,382 |
| David Slack | Former President and Chief Business Officer | $1,213,429 |
| Kristen K. Buck | M.D, Executive Vice President of Research & Development and Chief Medical Officer | $969,817 |
| Kristen Buck | M.D, Executive Vice President of Research & Development and Chief Medical Officer | $969,817 |
| James Nisco | Senior Vice President, Finance and Treasury and Chief Accounting Officer | $438,554 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David Mazzo | President and Chief Executive Officer | $1,929,933 |
| David J. Mazzo | President and Chief Executive Officer | $1,929,933 |
| Kristen Buck | M.D, Executive Vice President of Research & Development and Chief Medical Officer | $1,124,102 |
| Kristen K. Buck | M.D, Executive Vice President of Research & Development and Chief Medical Officer | $1,124,102 |
| David Slack | Former President and Chief Business Officer | $316,176 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kristen K. Buck | M.D, Executive Vice President of Research & Development and Chief Medical Officer | $1,858,333 |
| Kristen Buck | M.D, Executive Vice President of Research & Development and Chief Medical Officer | $1,858,333 |
| David Mazzo | Chief Executive Officer | $1,335,216 |
| David J. Mazzo | Chief Executive Officer | $1,335,216 |
| David Slack | Former President and Chief Business Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David J. Mazzo | President and Chief Executive Officer | $1,435,031 |
| David Mazzo | President and Chief Executive Officer | $1,435,031 |
| Douglas Losordo | Former Chief Medical Officer | $712,890 |
| Todd C. Girolamo | General Counsel and Corporate Secretary | $655,197 |
| Joseph Talamo | Former Chief Financial Officer | $495,138 |
| William K. Sietsema | Vice President, Global Regulatory Affairs | $400,177 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| David Mazzo | President and Chief Executive Officer | $1,539,651 |
| David J. Mazzo | President and Chief Executive Officer | $1,539,651 |
| Douglas Losordo | Former Chief Medical Officer | $890,011 |
| Joseph Talamo | Former Chief Financial Officer | $676,630 |
| Todd C. Girolamo | General Counsel and Corporate Secretary | $657,661 |
| William K. Sietsema | Vice President, Global Regulatory Affairs | $390,181 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| David J. Mazzo | President and Chief Executive Officer | $1,892,242 |
| David Mazzo | President and Chief Executive Officer | $1,892,242 |
| Douglas Losordo | Chief Medical Officer | $1,012,429 |
| Joseph Talamo | Chief Financial Officer | $834,955 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jeffrey Farrow | Class III member of the Board | Appointed | 2026-10-14 |
| Dr. Josh Lehrer | Chief Operating Officer and President of Lisata Therapeutics and Chief Executive Officer of Marea | Appointed | 2026-09-17 |
| Josh Lehrer | newly appointed Chief Operating Officer and President of Lisata Therapeutics and Chief Executive Officer of Marea | Appointed | 2026-09-17 |
| David J. Mazzo, Ph.D. | President | Resigned | 2026-09-17 |
| Josh Lehrer, M.D., M.Phil., FACC | President and Chief Operating Officer | Appointed | 2026-09-17 |
| Ted W. Love, M.D. | director | Appointed | 2026-09-17 |
| Dr. Kristen K. Buck, M.D. | Executive Vice President of R&D and Chief Medical Officer | Terminated | 2026-08-04 |
| James Nisco | Senior Vice President, Finance and Treasury and Chief Accounting Officer | Appointed | 2024-04-17 |
| Erkki Ruoslahti, M.D., Ph.D. | Board of Directors | Retired | 2023-07-11 |
| David Slack | Director | Resigned | 2023-05-01 |
| David Slack | President and Chief Business Officer | Terminated | 2023-05-01 |
| Steve Klosk | Director | Appointed | 2022-09-15 |
| Mohammad Azab | Director | Appointed | 2022-09-15 |
| Cynthia Flowers | Director | Appointed | 2022-09-15 |
| David Mazzo | Director | Appointed | 2022-09-15 |
| Gregory Brown | Chairman | Appointed | 2022-09-15 |
| Kristen K. Buck | Executive Vice President of R&D and Chief Medical Officer | Appointed | 2022-09-15 |
| Heidi Henson | Director | Appointed | 2022-09-15 |
| Erkki Ruoslahti | Director | Appointed | 2022-09-15 |
| David J. Mazzo | Chief Executive Officer | Appointed | 2022-09-15 |
| Mohammad Azab, M.B.A. | Director | Appointed | 2022-09-15 |
| Heidi Henson, C.P.A. | Director | Appointed | 2022-09-15 |
| David Slack | President and Chief Business Officer | Appointed | 2022-09-15 |
| Erkki Ruoslahti, Ph.D. | Director | Appointed | 2022-09-15 |
| Anne C. Whitaker | Director | Resigned | 2022-09-15 |
Leadership
- David J. Mazzo CEO, Board Member
- David J. Mazzo, Ph.D. CEO
- Gregory Brown Chairman
- Gregory Brown, M.D. Chairman
- Dr. Josh Lehrer COO
- Josh Lehrer COO
- Josh Lehrer, M.D., M.Phil., FACC COO
- Tariq Imam General Counsel
- James Nisco Chief Accounting Officer
- Anne Whitaker Board Member
- CLASS I Board Member
- Class III Board Member
- Cynthia Flowers Board Member
- Cynthia L. Flowers Board Member
- David Mazzo Board Member
- David Mazzo, Ph.D. Board Member
- David Slack Board Member
- David Slack, MBA Board Member
- Erkki Ruoslahti Board Member
- Erkki Ruoslahti, Ph.D. Board Member
- Gregory B. Brown Board Member
- Heidi Henson Board Member
- Heidi Henson, C.P.A. Board Member
- Jeffrey Farrow Board Member
- Michael H. Davidson Board Member
- Mohammad Azab Board Member
- Mohammad Azab, M.B.A. Board Member
- Steve Klosk Board Member
- Steven M. Klosk Board Member
- Ted W. Love, M.D. Board Member